E.H. Tan

1.5k citations

46 papers · 1.1k indexed · 1 hit paper · h-index 16

Impact in

Otorhinolaryngology top 1%
- Head and Neck Cancer Studies
Oncology top 5%
- Lung Cancer Research Studies
- Viral-associated cancers and disorders

Papers in ⓘ

Otorhinolaryngology 5
- Head and Neck Cancer Studies 5
Oncology 28
- Lung Cancer Research Studies 12
- HER2/EGFR in Cancer Research 5
- Cancer Treatment and Pharmacology 4
- Viral-associated cancers and disorders 3

Co-authors: Swan Swan Leong (9 shared papers)Wan‐Teck Lim (8 shared papers)Chee‐Keong Toh (6 shared papers)Balram Chowbay (3 shared papers)Ka-wing Fong (3 shared papers)Siew Wan Hee (3 shared papers)Nancy Wong (1 shared paper)Peter Ang (3 shared papers)
Journals: Annals of Oncology (17 papers)Journal of Clinical Oncology (6 papers)Journal of Thoracic Oncology (3 papers)Lung Cancer (2 papers)International Journal of Sports Medicine (2 papers)
Partner nations: Singapore China Taiwan

In The Last Decade

E.H. Tan

43 papers receiving 1.1k citations

Hit Papers

align trajectories log scale

Mitochondrial oxidative damage reprograms lipid metabolism of renal tubular epithelial cells in the diabetic kidney 2024 · 53 citations

Peers

Countries citing papers authored by E.H. Tan

Since Specialization

Citations

This map shows the geographic impact of E.H. Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E.H. Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E.H. Tan more than expected).

Fields of papers citing papers by E.H. Tan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E.H. Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E.H. Tan. The network helps show where E.H. Tan may publish in the future.

Co-authors

The 25 scholars most cited alongside E.H. Tan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with E.H. Tan Line = papers co-authored together E.H. Tan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 46 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma Annals of Oncology ·E.H. Tan, K. Khoo, Joseph Wee, Ka-wing Fong, Kim S Lee, Kit–Fai Lee, E.T. Chua, T. Tan, Hoon Seng Khoo-Tan, Tsung‐Lin Yang, E. Au, M. Tao, Yew Kwang Ong, E. Chua	1999	118
2	A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer Annals of Oncology ·C. Manegold, Nico van Zandwijk, A. Szczęsna, Petr Zatloukal, Joseph S. K. Au, Maria Błasińska-Morawiec, Piotr Serwatowski, Maciej Krzakowski, Jacek Jassem, E.H. Tan, Rebecca Benner, Antonella Ingrosso, Sandra J. Meech, David Readett, N. Thatcher	2011	117
3	Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol®-PM) in patients with solid tumors Annals of Oncology ·Wan‐Teck Lim, E.H. Tan, Chee‐Keong Toh, Siew Wan Hee, Swan Swan Leong, Peter Ang, Nancy Wong, Balram Chowbay	2009	116
4	A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma Annals of Oncology ·Whay Kuang Chia, W.-W. Wang, Melissa Ching Ching Teo, Wan‐Tien Tai, Wan‐Teck Lim, E.H. Tan, Swan Swan Leong, Yi Liu, J.J. Chen, Stephen Gottschalk, Han Chong Toh	2011	105
5	Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type Annals of Oncology ·Kian Fong Foo, E.H. Tan, Swan Swan Leong, Joseph Wee, Tao Tan, Ka-wing Fong, Lip Seng Koh, Bee‐Choo Tai, Lay-Geok Lian, David Machin	2002	94
6	Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer Annals of Oncology ·E.H. Tan, Janusz Rolski, Tomasz Grodzki, C. Schneider, U. Gatzemeier, Petr Zatloukal, Enrico Aitini, Giacomo Cartenì, H. Riska, Y H Tsai, Raymond P. Abratt	2009	56
7	Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma Annals of Oncology ·Joanne Ngeow, Wan‐Teck Lim, Swan Swan Leong, Mei‐Kim Ang, Chee‐Keong Toh, Fei Gao, Balram Chowbay, E.H. Tan	2010	53
8	Mitochondrial oxidative damage reprograms lipid metabolism of renal tubular epithelial cells in the diabetic kidney Cellular and Molecular Life Sciences ·Yanjuan Hou, E.H. Tan, Honghong Shi, Xiayu Ren, Xing Wan, Wenjie Wu, Yiliang Chen, Hiumin Niu, Guozhen Zhu, Jing Li, Yafeng Li, L J Wang Hit paper breakdown →	2024	53
9	GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine–cisplatin with vinorelbine–ifosfamide–cisplatin in metastatic non-small-cell lung cancer patients Annals of Oncology ·P.-J. Souquet, E.H. Tan, José Rodrigues Pereira, R. van Klaveren, Anna Price, U. Gatzemeier, M. Jaworski, J.P. Burillon, D. Aubert	2002	50
10	Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer Annals of Oncology ·E. Au, E.H. Tan, P T Ang	1998	48
11	Randomized study of vinorelbine–gemcitabine versus vinorelbine–carboplatin in patients with advanced non-small cell lung cancer Lung Cancer ·E.H. Tan, Aleksandra Szczęsna, Maciej Krzakowski, H.-N. Macha, U. Gatzemeier, K. Mattson, Martin Wernli, Pavel Reiterer, Rina Hui, Joachim von Pawel, Oscar Bertetto, Jean-Christophe Pouget, J.P. Burillon, Y Parlier, Raymond P. Abratt	2005	44
12	A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer Annals of Oncology ·E.H. Tan, Rodryg Ramlau, A Płużańska, H P Kuo, Martin Reck, Janusz Milanowski, Joseph S. K. Au, Enriqueta Felip, Pan‐Chyr Yang, D. Damyanov, С. В. Орлов, Mikhail Akimov, Paul Delmar, Laurent Essioux, Carina Hillenbach, Barbara Klughammer, P. McLoughlin, José Baselga	2010	35
13	Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. Journal of Clinical Oncology ·E.H. Tan, K. Park, W. T. Lim, M. Ahn, Q. S. Ng, J. S. Ahn, D. S. Tan, J. Sun, J. Jac, May Han, Francis Payumo, Marc Credi, K. McKee, Monette Cotreau, P. Bhargava, W. Slichenmyer	2011	30
14	Deficient catecholamine release as the basis of orthostatic hypotension in pernicious anaemia. Journal of Neurology Neurosurgery & Psychiatry ·Graeme Eisenhofer, D. G. Lambie, R.H. Johnson, E.H. Tan, E A Whiteside	1982	20
15	CD36 deletion ameliorates diabetic kidney disease by restoring fatty acid oxidation and improving mitochondrial function Renal Failure ·Huimin Niu, Xiayu Ren, E.H. Tan, Xing Wan, Yu Wang, Honghong Shi, Yanjuan Hou, Lihua Wang	2023	15
16	Phase III randomized trial of radiotherapy versus concurrent chemo-radiotherapy followed by adjuvant chemotherapy in patients with AJCC/UICC (1997) stage 3 and 4 nasopharyngeal cancer of the endemic variety Journal of Clinical Oncology ·Joseph Wee, E.H. Tan, Bee Choo Tai, Hee‐Kit Wong, Swan Swan Leong, Terence Tan, E.T. Chua, K. M. Lee, Edwin Yang, David Machin	2004	15
17	LBA2_PR Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7) Annals of Oncology ·K. Park, E.H. Tan, L. Zhang, Vera Hirsh, Kenneth J. O’Byrne, Michael Boyer, J.C-H. Yang, Tony Mok, M. Kim, Dan Massey, Victoria Zazulina, Luis Paz‐Ares	2015	12
18	Gastric carcinoma presenting with cellulitis-like cutaneous metastasis. PubMed ·Kian Fong Foo, Ming Tao, E.H. Tan	2002	12
19	Measuring Quality of Life in Chinese Cancer Patients: A New Version of the Functional Living Index for Cancer (Chinese) Annals of the Academy of Medicine Singapore ·YB Cheung, Gordon Ng, L.C. Wong, Wen Hsin Koo, E.H. Tan, M H Tay, D. Lim, Dennis Poon, C Goh, Say Beng Tan	2003	11
20	Triglyceride-Glucose Index is Significantly Associated with the Risk of Hyperuricemia in Patients with Nonalcoholic Fatty Liver Disease Diabetes Metabolic Syndrome and Obesity ·Jiaxin Qi, Xiayu Ren, Yanjuan Hou, Yaqing Zhang, Yanru Zhang, E.H. Tan, Lihua Wang	2023	10

About E.H. Tan

E.H. Tan is a scholar working on Otorhinolaryngology, Oncology, Pulmonary and Respiratory Medicine, Hematology and Nephrology, having authored 46 papers that have together received 1.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (22 papers), Lung Cancer Research Studies (12 papers), Lung Cancer Diagnosis and Treatment (7 papers), HER2/EGFR in Cancer Research (5 papers), Head and Neck Cancer Studies (5 papers), Cancer Treatment and Pharmacology (4 papers), Cancer therapeutics and mechanisms (4 papers) and Viral-associated cancers and disorders (3 papers). The work is most often cited by research in Otorhinolaryngology (283 citations), Oncology (605 citations), Pulmonary and Respiratory Medicine (399 citations), Immunology (156 citations) and Biomaterials (95 citations). E.H. Tan has collaborated with scholars based in Singapore, China and Taiwan. Frequent co-authors include Swan Swan Leong, Wan‐Teck Lim, Chee‐Keong Toh, Balram Chowbay, Ka-wing Fong, Siew Wan Hee, Nancy Wong, Peter Ang, Kian Fong Foo and U. Gatzemeier. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Journal of Thoracic Oncology, Lung Cancer and International Journal of Sports Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact